Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia

12 maj 2026 uppdaterad av: Valenta Pharm JSC

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Patients With Chronic Cholecystitis and Biliary Tract Dyskinesia

The aim of the study is to evaluate the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in patients with chronic cholecystitis and biliary dyskinesia.

Studieöversikt

Status

Rekrytering

Studietyp

Interventionell

Inskrivning (Beräknad)

300

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Moscow, Ryssland, 119571
        • Rekrytering
        • Unimed-C Jsc
        • Kontakt:
          • Olga Orlova, MD
          • Telefonnummer: +7 (919) 994-90-14
          • E-post: orlelik@mail.ru
      • Moscow, Ryssland, 117556
        • Rekrytering
        • State Budgetary Institution of Healthcare of Moscow "City Polyclinic No. 2 of the Moscow Department of Healthcare"
        • Kontakt:
      • Moscow, Ryssland
        • Rekrytering
        • The State Budgetary Healthcare Institution of the Moscow Region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky"
        • Kontakt:
      • Novosibirsk, Ryssland
        • Rekrytering
        • Limited Liability Company "ErSi Medical"
        • Kontakt:
      • Perm, Ryssland, 614990
        • Rekrytering
        • Federal State Budgetary Educational Institution of Higher Education "Academician E.A. Wagner Perm State Medical University" of the Ministry of Healthcare of the Russian Federation
        • Kontakt:
      • Saint Petersburg, Ryssland, 194358
        • Rekrytering
        • St. Petersburg State Budgetary Healthcare Institution "City Polyclinic No. 117"
        • Kontakt:
      • Saint Petersburg, Ryssland, 196143
        • Rekrytering
        • Limited Liability Company "Research Center Eco-Safety"
        • Kontakt:
      • Saint Petersburg, Ryssland, 196158
        • Rekrytering
        • Limited Liability Company "Clinic Zvezdnaya"
        • Kontakt:
      • Saratov, Ryssland, 410071
        • Rekrytering
        • State Healthcare Institution "Saratov City Clinical Hospital No. 5"
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  1. Males and females aged 18-70 years.
  2. Diagnosed with chronic cholecystitis (K81.1) and/or dyskinesia of the cystic duct or gallbladder (K82.8) prior to enrollment; diagnosis supported by clinical history of exacerbations and remissions and/or imaging/laboratory findings.
  3. Upper abdominal pain or discomfort attributable to gallbladder or biliary tract dysfunction (per investigator assessment), accompanied by ≥1 of the following: heartburn, belching, nausea, abdominal bloating, borborygmi (stomach rumbling), flatulence, constipation, or diarrhea.
  4. Maximum severity of pain/discomfort in the upper abdomen over the past week is 40 mm or more on the VAS (Visual Analog Scale).
  5. Severity of gastrointestinal symptoms according to the GSRS (Gastrointestinal Symptom Rating Scale) questionnaire is at least 30 points.
  6. The total bilirubin level does not exceed 2 times the upper limit of normal (no more than 42 μmol/L).
  7. Women who are either sexually abstinent or using effective contraception methods (e.g. intrauterine devices, contraceptive patches, long-acting injectable contraceptives, or double barrier methods) for at least 8 weeks before and 3 weeks after the end of the study, with a confirmed negative pregnancy test, as well as women with documented infertility or non-childbearing status (e.g. hysterectomy, tubal ligation, infertility or menopause for more than 1 year) or men using barrier contraceptives throughout the study and for 3 weeks after its completion, or men unable to conceive (documented conditions: vasectomy, infertility).
  8. Signed and dated informed consent from.

Non-inclusion Criteria:

  1. Gastric or duodenal ulcer, erosive gastroesophageal reflux disease (GERD), or other inflammatory/erosive gastrointestinal diseases in the acute stage, unless stable remission for ≥ 1 year since the last exacerbation.
  2. Indication for surgical or endoscopic intervention due to exacerbation of chronic cholecystitis or complications of biliary tract dyskinesia.
  3. Toxic megacolon.
  4. Paralytic ileus.
  5. Gilbert's syndrome.
  6. Choledocholithiasis (or a high risk of its development, as determined by the investigator);
  7. Impaired bile outflow due to adhesions in the abdominal cavity.Abdominal adhesion disease.
  8. Irritable bowel syndrome, non-specific ulcerative colitis, Crohn's disease.
  9. Gastrointestinal malignancy (including history of) or suspected gastrointestinal malignancy (e.g., blood in stool, unexplained weight loss, fever, anemia).
  10. Any other oncological diseases known at the time of screening, or suspicion thereof.
  11. History of gastrointestinal surgery, including cholecystectomy or endoscopic sphincterotomy (appendectomy excluded).
  12. Use of prohibited therapy medications within 3 days prior to randomization.
  13. History of mental illnesses.
  14. Chronic heart failure IIb-III stages and/or III-IV functional classes according to NYHA, angina pectoris III-IV functional classes.
  15. Chronic kidney disease stage IIIa-V (according to NKF/KDOQI, 2006).
  16. History of or current hepatic impairment; or liver test abnormalities: AST, ALT, ALP, or GGT >3 above the upper limit of normal (ULN); total bilirubin >2 ULN or clinical jaundice.
  17. HIV, syphilis, viral hepatitis B or C, including in history.
  18. Lactose intolerance, lactase deficiency, and glucose-galactose malabsorption syndrome.
  19. Liver cirrhosis.
  20. Hypersensitivity to the active ingridient or any of the excipients of the drug 4-MUST.
  21. Severe, decompensated, or unstable somatic conditions that are life-threatening, worsen prognosis, or preclude safe study participation.
  22. Diabetes mellitus in a state of subcompensation and decompensation.
  23. Systemic connective tissue diseases.
  24. Autoimmune diseases.
  25. Indication for hemodialysis procedures.
  26. Epilepsy or seizures of unclear etiology, including in history.
  27. Alcoholism, substance abuse or drug addiction, including in history.
  28. Uncorrected electrolyte disturbances.
  29. QTcF interval on a 12-lead electrocardiogram (ECG) ≥430 ms in men and ≥450 ms in women.
  30. Episodes of constipation during the last 3 months that required the prescription of drug therapy.
  31. History of surgery within 6 month prior to screening.
  32. Women during pregnancy or lactation; women planning to become pregnant within the next 6 months.
  33. Patients who require prohibited concomitant therapy within this study framework.
  34. Participation in another clinical trial within the last 3 months prior to the screening visit date.
  35. Unwillingness or inability to comply with study procedures and protocol requirements..
  36. Other conditions that, in the investigator's judgement, may preclude the patient's participation in the study.

Exclusion Criteria:

  1. Incorrect enrollment of a patient in the study (failure to meet inclusion/exclusion criteria at the time of randomization).
  2. Lack of Efficacy. Study treatment will be discontinued if no clinical improvement is observed by Visit 3 (Day 15 ± 1), defined as persistence or worsening of upper abdominal pain/discomfort (assessed by Visual Analog Scale [VAS]) compared to baseline. Upon discontinuation, alternative therapy will be initiated at the investigator's discretion.
  3. Patient non-compliance (a compliant patient is defined as one who has taken at least 202 and no more than 303 tablets).
  4. Requirement for prohibited concomitant therapy.
  5. Use of Duspatalin® (INN: mebeverine) for more than 3 consecutive days or for more than 5 days in total throughout the study.
  6. If the investigator judges that comtinued participation in the study would harm the patient.
  7. Pregnancy or the need for breastfeeding.
  8. Major protocol deviation by the subject with respect to procedures outlined in the Informed Consent Form (ICF).
  9. Withdrawal of informed consent by the subject (decision to discontinue study participation).
  10. Lost to follow-up: Inability to contact the subject after ≥3 documented attempts via mobile phone, landline (if applicable), and designated emergency contact.
  11. Emergence during the study of any diseases or conditions that worsen the patient's prognosis, making it impossible for the patient to continue participating in this clinical trial.
  12. Any other reasons, including administrative issues, that in the investigator's judgement may interfere with subject's ability to comlete the study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: 4-MUST
4-MUST: 384 mg (3 tablets), orally three times a day (TID), 30 min before meals. Total daily dose - 1152 mg.
128 mg trimebutin 4-metybelliferylsulfattablett.
Andra namn:
  • trimebutin 4-metybelliferylsulfat
Placebo-jämförare: Placebo
Placebo: 3 tablets, orally three times a day (TID), 30 min before meals.
Placebotablett.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Mean reduction in the severity of pain/discomfort in the upper abdomen on the VAS by day 29 compared to baseline
Tidsram: Day 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 29 ± 1

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Säkerhet och tolerabilitet: Vitala tecken - Systoliskt blodtryck (SBP)
Tidsram: Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
SBP, MMHG
Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Säkerhet och tolerabilitet: Vitala tecken - Diastoliskt blodtryck (DBP)
Tidsram: Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
DBP, MMHG
Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Säkerhet och tolerabilitet: Vital Signs - Respiratory Rate (RR)
Tidsram: Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Rr, andetag per minut
Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Säkerhet och tolerabilitet: Vital Signs - Post (HR)
Tidsram: Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
HR, beats per minut
Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Säkerhet och tolerabilitet: Vitala tecken - Kroppstemperatur
Tidsram: Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Kroppstemperatur, Celsius skala
Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Fysiska undersökningsresultat: Kardiovaskulärt system
Tidsram: Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
En bedömning av tillståndet för hjärt -kärlsystemet vid fysisk undersökning (normalt tillstånd eller lista över onormala tillstånd, om någon)
Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Fysiska undersökningsresultat: matsmältningskanalen
Tidsram: Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
En bedömning av tillståndet för matsmältningskanalen vid fysisk undersökning (normalt tillstånd eller lista över onormala tillstånd, om några)
Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Fysiska undersökningsresultat: Endokrin system
Tidsram: Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
En bedömning av tillståndet för det endokrina systemet vid fysisk undersökning (normalt tillstånd eller lista över onormala tillstånd, om någon)
Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Fysiska undersökningsresultat: Muskuloskeletalsystem
Tidsram: Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
En bedömning av tillståndet för muskuloskeletalsystemet vid fysisk undersökning (normalt tillstånd eller lista över onormala tillstånd, om några)
Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Fysiska undersökningsresultat: nervsystemet
Tidsram: Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
En bedömning av nervsystemets tillstånd vid fysisk undersökning (normalt tillstånd eller lista över onormala tillstånd, om några)
Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Fysiska undersökningsresultat: Sensoriska system
Tidsram: Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
En bedömning av tillståndet för de sensoriska systemen vid fysisk undersökning (normalt tillstånd eller lista över onormala tillstånd, om några)
Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Fysiska undersökningsresultat: Hud/synliga slemhinnor
Tidsram: Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
En bedömning av tillståndet för huden/synliga slemhinnor vid fysisk undersökning (normalt tillstånd eller lista över onormala tillstånd, om några)
Screening, dag 1, dag 8 ± 1, dag 15 ± 1, dag 22 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Hemoglobin
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Hemoglobin (g/l)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Hematokrit
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Hematokrit (%)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Röd blodkroppsantal
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Röd blodkroppsantal (celler/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Trombocytantal
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Trombocytantal (celler/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Leukocytantal
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Leukocytantal (celler/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Erytrocytsedimentationshastighet
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Erytrocyt sedimentationsgrad (mm/h)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Myelocyter
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Leukocytformel (myelocyter, %)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Bandneutrofiler
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Leukocytformel (bandneutrofiler, %)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Segmenterade neutrofiler
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Leukocytformel (segmenterade neutrofiler, %)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Eosinofiler
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Leukocytformel (eosinofiler, %)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Basofiler
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Leukocytformel (basofiler, %)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Monocyter
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Leukocytformel (monocyter, %)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Kliniskt blodprov - Lymfocyter
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Leukocytformel (lymfocyter, %)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Blodkemi - Glukos
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Glukoskoncentration (mmol/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Blodkemi - kolesterol
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Total kolesterolkoncentration (mmol/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Blodkemi - Protein
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Total proteinkoncentration (G/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Blodkemi - Bilirubin
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Total bilirubinkoncentration (mikromol/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Blodkemi - Kreatinin
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Kreatininkoncentration (mikromol/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Blodkemi - Alkaliskt fosfatas
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Alkalisk fosfatasaktivitet (U/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Blodkemi - Alanintransaminas
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Alanintransaminasaktivitet (U/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Blood Chemistry - Aspartate Transaminase
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Aspartat transaminasaktivitet (U/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Blood Chemistry - Gamma -GTP
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Gamma-glutaryltranspeptidasaktivitet (U/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Urinalys - Specifik vikt
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Urinens specifika tyngdkraft
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: urinalys - pH
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
urinens ph
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: urinalys - protein
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Proteinkoncentration (G/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Urinalys - Glukos
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Glukoskoncentration (mmol/L)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Urinalys - Röda blodkroppar
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Röd blodkroppsinnehåll (nummer i sikte)
Screening, dag 15 ± 1, dag 29 ± 1
Resultat av laboratorie- och instrumentella undersökningar: Urinalys - Vita blodkroppar
Tidsram: Screening, dag 15 ± 1, dag 29 ± 1
Vita blodkroppsinnehåll (nummer i sikte)
Screening, dag 15 ± 1, dag 29 ± 1
Mean reduction in the severity of pain/discomfort in the upper abdomen according to VAS by days 2-28 from the start of therapy
Tidsram: Day 2 - Day 28
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 2 - Day 28
Frequency of response to therapy (proportion of patients in the group with a reduction in the severity of pain/discomfort in the upper abdomen according to VAS by 30% or more) by days 8, 15, 22, and 29 following treatment initiation.
Tidsram: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Frequency of response to therapy (proportion of patients in the group with a reduction in the severity of pain/discomfort in the upper abdomen according to VAS by 50% or more) by days 8, 15, 22, and 29 following treatment initiation.
Tidsram: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Time to therapeutic response (reduction in the severity of pain/discomfort in the upper abdomen according to VAS by 30% or more)
Tidsram: Day 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 29 ± 1
Time to therapeutic response (reduction in the severity of pain/discomfort in the upper abdomen according to VAS by 50% or more)
Tidsram: Day 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 29 ± 1
Frequency of clinical recovery (proportion of patients in the group with a reduction in the severity of pain/discomfort in the upper abdomen according to VAS to 10 mm or less) by days 8, 15, 22, and 29 following treatment initiation.
Tidsram: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Time to clinical recovery (reduction in the severity of pain/discomfort in the upper abdomen according to VAS to 10 mm or less)
Tidsram: Day 29 ± 1
Visual analogue scale (VAS) from 0 to 100 mm, where 0 is "no pain", and 100 is "the worst pain one can imagine"
Day 29 ± 1
Change in the total score of gastroenterological symptom severity according to the GSRS questionnaire by days 8, 15, 22, and 29 following treatment initiation.
Tidsram: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
The Gastrointestinal Symptom Rating Scale (GSRS) is a self-administered questionnaire designed to assess gastrointestinal symptoms and their severity. It consists of 15 items categorized into five domains: Abdominal pain (including stomach pain and nausea), Reflux (heartburn and acid reflux), Indigestion (bloating, burping, and flatulence), Constipation (hard stools and incomplete evacuation), Diarrhea (loose stools and urgency). Respondents rate their symptoms on a 7-point Likert scale, where 1 indicates no discomfort and 7 indicates very severe discomfort.
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Change in dyspeptic symptom severity, as assessed by the GSRS, expressed as score changes from baseline in the Abdominal Pain, Reflux, Indigestion, Diarrhea, and Constipation syndrome subscales at Days 8, 15, 22, and 29 following treatment initiation.
Tidsram: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
The Gastrointestinal Symptom Rating Scale (GSRS) is a self-administered questionnaire designed to assess gastrointestinal symptoms and their severity. It consists of 15 items categorized into five domains: Abdominal pain (including stomach pain and nausea), Reflux (heartburn and acid reflux), Indigestion (bloating, burping, and flatulence), Constipation (hard stools and incomplete evacuation), Diarrhea (loose stools and urgency). Respondents rate their symptoms on a 7-point Likert scale, where 1 indicates no discomfort and 7 indicates very severe discomfort.
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Change in the severity of individual symptoms of dyspeptic disorders according to the GSRS questionnaire in points by days 8, 15, 22, and 29 following treatment initiation.
Tidsram: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
The Gastrointestinal Symptom Rating Scale (GSRS) is a self-administered questionnaire designed to assess gastrointestinal symptoms and their severity. It consists of 15 items categorized into five domains: Abdominal pain (including stomach pain and nausea), Reflux (heartburn and acid reflux), Indigestion (bloating, burping, and flatulence), Constipation (hard stools and incomplete evacuation), Diarrhea (loose stools and urgency). Respondents rate their symptoms on a 7-point Likert scale, where 1 indicates no discomfort and 7 indicates very severe discomfort.
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Change in quality of life according to the total score on the SF-36 questionnaire by day 29 from treatment initiation.
Tidsram: Day 29 ± 1
SF-36 (Short Form 36 Health Survey) is a self-reported questionnaire. It consists of 36 items that cover eight health domains: Physical functioning, Role limitations due to physical health, Role limitations due to emotional problems, Bodily pain, General health perceptions, Vitality (energy and fatigue), Social functioning, Mental health. SF-36 produces a profile of scores for each domain, which can be summarized into two main components: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Scores range from 0 to 100, where lower scores indicate greater disability and higher scores indicate better health.
Day 29 ± 1
Change in the total score on the PAGI-SYM questionnaire by days 15 and 29 from treatment initiation.
Tidsram: Day 15 ± 1, and 29 ± 1
PAGI-SYM (Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index) is a patient-reported questionnaire designed to assess the severity of symptoms in upper gastrointestinal disorders (GERD, dyspepsia, and gastroparesis). It consists of 20 items grouped into six subscales: Heartburn/Regurgitation, Fullness/Early Satiety, Nausea/Vomiting, Bloating, Upper Abdominal Pain, and Lower Abdominal Pain. Each symptom is rated on a 6-point Likert scale from 0 (none) to 5 (very severe). The questionnaire provides a profile of scores for each subscale, as well as a total score. Higher scores indicate greater symptom severity.
Day 15 ± 1, and 29 ± 1
change in the total score on the Visceral Sensitivity Index questionnaire by days 15 and 29 from the start of therapy
Tidsram: Day 15 ± 1, and 29 ± 1
VSI (Visceral Sensitivity Index) is a patient-reported questionnaire measuring gastrointestinal-specific anxiety (cognitive, affective, and behavioral responses to GI sensations). It consists of 15 items rated on a 6-point scale, producing a total score from 0 to 75. Higher scores indicate greater GI-specific anxiety. Originally validated in IBS patients, it is now used across various GI disorders.
Day 15 ± 1, and 29 ± 1
Change in the total score on the Emotional Distress - Depression - Short Form 4a questionnaire by days 8, 15, 22, and 29 from the start of therapy
Tidsram: Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Emotional Distress - Depression - Short Form 4a (PROMIS Depression SF 4a) is a patient-reported questionnaire assessing depression symptoms over the past 7 days. It consists of 4 items rated on a 5-point scale. Raw scores (4-20) are converted to a standardized T-score (mean=50, SD=10). Higher scores indicate greater depression severity.
Day 8 ± 1, 15 ± 1, 22 ± 1, and 29 ± 1
Safety and Tolerability: adverse event (AE) rate
Tidsram: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Frequency of adverse events (AEs) or serious AEs (SAEs)
From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Safety and Tolerability: adverse event (AE) number
Tidsram: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Number of adverse events (AEs) or serious AEs (SAEs)
From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Safety and Tolerability: AEs associated with the study drug
Tidsram: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Number and frequency of AEs associated with the study drug
From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Safety and Tolerability: SAEs associated with the study drug
Tidsram: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Number and frequency of SAEs associated with the study drug
From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Safety and Tolerability: treatment discontinuation
Tidsram: From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Percentage of patients who discontinued treatment due to the occurrence of AEs/SAEs
From screening (and signing informed consent form) to the end of the study (Day 36 ± 2)
Physical examination results: respiratory system
Tidsram: Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1
An assessment of the condition of the respiratory system on physical examination (normal condition or list of abnormal conditions, if any)
Screening, day 1, day 8 ± 1, day 15 ± 1, day 22 ± 1, day 29 ± 1
Results of laboratory and instrumental examinations: blood chemistry - CRP
Tidsram: Screening, day 15 ± 1, day 29 ± 1
C-reactive protein, CRP (mg/L)
Screening, day 15 ± 1, day 29 ± 1
Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate
Tidsram: Screening, day 1, day 29 ± 1
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: heart rate (beats per minute)
Screening, day 1, day 29 ± 1
Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval
Tidsram: Screening, day 1, day 29 ± 1
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: PQ interval (is the period, measured in milliseconds, that extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex)
Screening, day 1, day 29 ± 1
Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex
Tidsram: Screening, day 1, day 29 ± 1
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: QRS complex (the QRS complex is the combination of three of the graphical deflections seen on a typical electrocardiogram)
Screening, day 1, day 29 ± 1
Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval
Tidsram: Screening, day 1, day 29 ± 1
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: corrected QT interval (distance from the beginning of the QRS complex to the end of the T wave) (Frederica correction)
Screening, day 1, day 29 ± 1

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

12 december 2025

Primärt slutförande (Beräknad)

31 december 2027

Avslutad studie (Beräknad)

31 december 2027

Studieregistreringsdatum

Först inskickad

12 maj 2026

Först inskickad som uppfyllde QC-kriterierna

12 maj 2026

Första postat (Faktisk)

19 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 maj 2026

Senast verifierad

1 mars 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • GIB-03-04-2025

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera